Current and Emerging Immunotherapies for Systemic AL Amyloidosis.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Systemic light-chain (AL) amyloidosis is a rare plasma cell neoplasm causing organ dysfunction due to amyloid deposition.
• Cardiac involvement significantly worsens prognosis in AL amyloidosis.
• Effective treatment requires targeting the underlying plasma cell clone and amyloid deposits.

Purpose of the Study:

• To provide a comprehensive review of current and emerging therapies for systemic AL amyloidosis.
• To highlight recent advances in immunotherapeutic strategies for AL amyloidosis.
• To discuss future directions in treating this complex disease.

Main Methods:

• Review of current literature on AL amyloidosis treatment strategies.
• Analysis of approved therapies, including quadruplet therapy (cyclophosphamide, bortezomib, dexamethasone, daratumumab).
• Exploration of novel therapeutic approaches, including monoclonal antibodies (CAEL 101, Birtamimab) and stem cell transplantation.

Main Results:

• Quadruplet therapy (DaraCyborD) is the standard first-line induction for AL amyloidosis.
• Autologous stem cell transplantation is an option for patients not achieving complete hematologic response.
• Monoclonal antibodies targeting amyloid deposits are in Phase 3 trials for advanced cardiac AL amyloidosis.

Conclusions:

• Treatment strategies for AL amyloidosis focus on eradicating the clonal plasma cells and preventing further amyloid deposition.
• Emerging immunotherapies, particularly monoclonal antibodies, offer potential for direct amyloid removal and organ repair.
• Continued research into novel treatments is crucial for improving outcomes in AL amyloidosis.